592687 Disclosed herein is a compound of Formula I wherein: Ring A is a 7-azanorbornanyl or 8-azabicyclo(3.2.1)octanyl ring system R1 is -CH3, -CF3 or -CN, R2 is hydrogen, -CH3, -CF3, -OH, or -CH2OH, R3 is hydrogen, -CH3, -OCH3, or -CN provided that both R2 and R3 are not simultaneously hydrogen, Ra is hydrogen or a silyl protecting group, and one of X and Y is nitrogen and the other is carbon the use thereof in the treatment of a disease, such as cystic fibrosis or a disease associated with modulation of CFTR activity and a process for the preparation thereof comprising: reacting a compound of formula 2a with an amine of formula 3 to provide a compound of formula 2b, converting the compound of formula 2b to the amine of formula 2e via hydrogenation, reacting the amine of formula 2c with an acid of formula Id to provide a compound of formula Ic, and optionally further comprising a deprotection step wherein Ra is a silyl protecting group. Exemplary compounds include: N-(6-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)pyridin-3-yl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, and N-(6-(7-azabicyclo[2.2.1]heptan-7-yl)-4-methylpyridin-3-yl)-S-methyl-4-oxo-1,4-dihydroquinohne-3-carboxamide hydrochloride.
